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To explore the mechanisms of the effects of 
sucralfate on the stomach, we investigated the 
action of sucrose octasulfate (SOS), a constitu- 
ent of sucralfate, on the function of canine 
gastric parietal cells and somatostatin cells 
and in the isolated perfused intact rat stom- 
ach. Somatostatin cells from the canine gastric 
fundus were isolated by EDTA-collagenase dis- 
persion and counterflow elutriation, and soma- 
tostatin-like immunoreactivity (SLI) release in 
response to SOS was measured by radioimmu- 
noassay. Similar methods were used to isolate 
gastric parietal cells, in which gastric acid se- 
cretion was measured by uptake of a radiola- 
beled weak base, [14Claminopyrine. SLI release 
by the intact rat stomach was examined in an 
isolated vascularly perfused rat stomach 
model. SOS, either alone or co-administered 
with epinephrine or gastrin heptadecapeptide 
(Gli’), dose-dependently stimulated SLI release 
by isolated canine fundic D-cells. At the high- 
est doses, SOS potentiated the effect of epi- 
nephrine but not 617. Similarly, SOS potenti- 
ated the stimulating effect of dibutyryl cyclic 
adenosine 3’,5’-monophosphate (DBcAMP), but 
not 12-O-tetradecanoylphorbol 13-acetate 
(TPA). The effect of SOS on SLI release could 
be inhibited by octreotide, a somatostatin ana- 
logue. SOS did not alter acid secretion by cul- 
tured canine parietal cells either in the basal 
state or when coadministered with acid secre- 
tagogues. In isolated perfused rat stomach 
studies, SOS produced a significant (60% 
greater than basal) increase in SLI secretion. 
There was a similar effect when SOS was per- 
fused against a background of isoproterenol. 
SOS stimulates SLI release from gastric soma- 
tostatin cells and from the isolated perfused 
stomach but has no direct effect on gastric 
From the Department of Internal Medicine, University of Michigan Medical Cen- 
ter, Ann Arbor, Michigan. 
These studies were supported by grant NIH ROlDK33500 and funds from 
the University of Michigan Gastrointestinal Peptide Research Center (grant 
P30DK34933). 
Requests for reprints should be addressed to Tadataka Yamada, M.D., 3912 
Taubman Center, University of Michigan Medical Center, Ann Arbor, Michigan 
48109-0362. 
parietal cells. These actions of SOS may medi- 
ate in part the apparent ability of sucralfate to 
enhance gastric mucosal defense. 
S ucralfate, an aluminum salt of the sulfated di- saccharide, sucrose octasulfate (SOS), pro- 
motes healing of experimentally induced gastric 
ulcers in animals and spontaneous duodenal ulcers 
in humans [1,2]. Among the mechanisms that have 
been proposed to account for these cytoprotective 
effects are increased secretion of gastric mucus, al- 
teration of the physiochemical and, thereby, pro- 
tective properties of mucus, local release of prosta- 
glandin, reduction of gastric pepsin activity, ab- 
sorption of bile salts, and direct binding to mucosa 
[3-81. However, neither sucralfate nor SOS, its 
presumed active constituent, is known to influence 
the secretion of gastric acid or regulatory peptides 
by the stomach. One of these regulatory peptides, 
somatostatin, is a major local regulator of gastric 
physiology, modulating acid secretion, endocrine 
function, and probably blood flow [9]. For these 
reasons, somatostatin has been proposed as having 
an important role in regulation of ulcer healing [ 101. 
We undertook these studies, therefore, to examine 
whether SOS may exert its ulcer-healing effects in 
part via release of endogenous gastric somato- 
statin. 
METHODS 
Isolated Cell Studies 
Cells were dispersed from freshly obtained adult 
canine gastric mucosa as reported previously 
[11,12]. Briefly, the stomachs were divided into 
fundic and antral segments and the fundic mucosa 
was bluntly separated from the submucosa. Muco- 
sal fragments were incubated sequentially in colla- 
genase [0.35 mg/mL) and ethylene diaminetetra- 
acetic acid (EDTA, 1 mM) and the dispersed cells 
were separated by counter-flow elutriation using a 
JE-10X elutriation system (Beckman Instruments, 
Fullerton, California). The somatostatin cell frac- 
tions were collected, then layered at a density of 
2.5-3.5 x lo6 cells/well and cultured at 37°C on a 
bed of collagen in a 24-mm multiwell tissue culture 
plate in 1 mL of Ham’s F-12IDulbecco’s modified 
Eagle’s (50:50) medium containing 10% dialyzed 
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dog serum, insulin (8 mg/mL), hydrocortisone (1 
mg/mL), and gentamicin (100 pg/mL) in the pres- 
ence of 95% air, 5% COs. The fractions used for 
study consisted of roughly 70% somatostatin- 
containing D-cells on the basis of immunocytochem- 
istry [ll]. After 40 hours stabilization, the cells 
were incubated in Earle’s balanced salt solution 
containing various test substances for a Z-hour test 
period and the somatostatin-like immunoreactivity 
(SLI) released into the media was measured by ra- 
dioimmunoassay [131. 
Fractions enriched in parietal cells were isolated 
to a purity of 60-70% in similar fashion as previ- 
ously described [14]. Viability of the parietal cells 
exceeded 95% as judged by trypan blue exclusion. 
We added [14C]aminopyrine (0.1 &i, specific 
activity = 80 &i per pmol) and various test mate- 
rials to a 4 x lo6 cell suspension in 2 ml Earle’s bal- 
anced salt solution containing N-2-hydroxyethyl- 
piperazine-N’-2-ethanesuifonic acid (HEPES) (19 
mM) and bovine serum albumin (0.1%). The mix- 
ture was gassed with 95% Oz, 5% COz, and incu- 
bated for 20 minutes at 37°C. Thereafter, cells were 
pelleted by centrifugation and accumulation of 
[‘4C]aminopyrine within the pellet was measured 
by scintigraphy. 
Gastric Perfusion Studies 
Perfusion of vascularly intact isolated rat stom- 
achs was performed as described previously [15]. 
Briefly, male Sprague-Dawley rats (250-400 g) 
were fasted with free access to water for 16-24 
hours and anesthetized by intraperitoneal adminis- 
tration of sodium pentobarbital. Stomachs were iso- 
lated and perfused according to the previously pub- 
lished modification of the technique of Grodski et al 
[ 161. This involves dissecting the stomach free from 
the esophagus and duodenum and removing the 
pancreas, while maintaining the aortic remnant, 
celiac artery, and portal vein. The isolated stom- 
achs were transferred immediately to a heated 
(37°C) stand, whereupon the aortic remnant and 
portal vein were cannulated. The preparation was 
perfused at a rate of 3 ml/minute with oxygenated 
(95% Os-5% COa) Krebs-Ringer buffer containing 
3% dextran T-40 and 0.2% bovine serum albumin. 
Portal venous effluent was collected at l-minute 
intervals and then stored at -20°C for subsequent 
measurement of SLI and gastrin by radioimmuno- 
assay [13]. In all experiments, the responsiveness 
of the preparation was established by administra- 
tion of isoproterenol, a known secretagogue of SLI, 
before and after the test periods. 
RESULTS 
In our initial experiments we examined the ef- 
fects of SOS on basal secretion of SLI as well as 
SLI secretion induced by epinephrine or hep- 
tadecapeptide (G17). As shown in Figure 1, SOS 
dose-dependently stimulated SLI secretion in all 
three circumstances. Of particular interest was the 
observation that the combined stimulator-y action of 
SOS at the two highest doses (10 and 20 mg/mL) 
against a background of epinephrine exceeded the 
sum of the SLI responses to each secretagogue 
administered alone. In contrast, a similar potentiat- 
ing phenomenon was not observed when SOS and 
G17 were combined. From these data, we inferred 
that SOS and epinephrine may interact via separate 
signal transduction mechanisms. In previous stud- 
ies we have shown that epinephrine stimulates ca- 
nine fundic D-cells via cyclic adenosine monophos- 
phate (CAMP) generation, whereas gastrin’s effects 
are mediated by induction of membrane inositol 
phospholipid turnover and activation of protein ki- 
nase C [17,18]. To examine further the potential 
interactions of SOS with these intracellular signal 
transduction mechanisms, we investigated the SLI 
Figure 1. The effect of sucrose octasulfate 
(SOS), either alone or in combination with epi- 
nephrine (EPI) or gastrin heptadecapeptide 
(G17) on somatostatin-like immunoreactivity 
(SLI) release by fundic D-cells. The data repre- 
sent means t standard errors from four sepa- 
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Figure 2. The effect of sucrose octasulfate 
(SOS), either alone or in combination with dibu- 
tyryl cyclic adenosine 3’,5’-monophosphate 
(DBcAMP) or 12&etradecanoylphorbol~l3- 
acetate (TPA) and somatostatin-like immunore- 
activity (SLI) release by fundic D-cells. The data 
are from a single-cell preparation and are repre- 
sentative of data obtained from two other prepa- 
rations 
Figure 3. The effect of octreotide (Sandostatin) 
on somatostatin-like immunoreactivity (SLI) re- 
lease in response to sucrose octasulfate (SOS), 
either alone or in combination with other secre- 
tagogues. The data are from a single-cell prepa- 
ration and are representative of data obtained 
from two other preparations. 
response to combined administration of SOS and 
either dibutyryl CAMP (DBcAMP) or E-O- 
tetradecanoylphorbol l&acetate (TPA), a direct 
stimulant of protein kinase C. As shown in Figure 
2, SOS potentiated the SLI-stimulatory action of 
DBcAMP but not that of TPA. 
To determine whether the effect of SOS repre- 
sented nonspecific irreversible stimulation of, or 
possibly even damage to, D-cells, we investigated 
whether the stimulation of SLI release by SOS 
could be inhibited. As shown in Figure 3, 
octreotide, a functional analogue of somatostatin 
that is not immunoreactive in our somatostatin ra- 
dioimmunoassay, inhibited at least partially the 
SLI-stimulating effect of SOS alone and SOS in 
combination with either epinephrine, G17, 
DBcAMP, or TPA. We also explored whether the 
stimulatory effect of SOS was selective for D-cells 
by examining its action on gastric parietal cells. As 
shown in Figure 4, SOS in a dose that was effective 
in stimulating SLI secretion did not affect aminopy- 
rine uptake by isolated enriched parietal cells, ei- 
ther basally or when co-administered with acid se- 
cretagogues. 
We examined whether the effects of SOS on 
D-cells could be reproduced in a more intact physio- 
logic system, the isolated perfused whole stomach. 
As shown in Figure 5, SOS produced a modest but 
significant increase in basal SLI release. When SOS 
was administered with a background infusion of 
low-dose isoproterenol, a similar modest increase in 
SLI concentration was observed in the portal ve- 
nous effluent (Figure 6). 
COMMENTS 
Although sucralfate has become a widely used 
agent to prevent or treat gastric and intestinal 
mucosal injury, the cellular basis of its action is un- 
certain. Much of the effort to determine the mecha- 
nism of sucralfate’s efficacy has been focused on its 
ability to enhance mucosal defense. Among the fac- 
tors that have been implicated in this function are 
the ability of sucralfate, or its active component 
SOS, to enhance prostaglandin production, mucus 
secretion and physiochemistry, and epithelial elec- 
trical potential [3,4,8,19]. The cells that function as 
targets for sucralfate or SOS have not been identi- 
fied. One potential target cell is the gastric D-cell 
2A-54s August 8, 1991 The American Journal of Medicine Volume 91 (suppl 2A) 
SYMPOSIUM ON SUCRALFATE / LUCEY ET AL 
Figure 4. The effect of sucrose octasulfate 
(SOS) on uptake of radiolabeled aminopyrine by 
enriched canine parietal cells either alone or 
with coadministration of isomethylxanthine 
(IMX); histamine (H) plus IMX, heptadecapeptide 
(G17) plus IMX, and carbachol (CARB) plus IMX. 
The data represent means + standard error 
from three separate cell preparations. 
+ SOS 10 mglml 
u CONTROL IMX 
10 -5 M 
MA; + MA;,; MAX + 
CARB 
10 -s M 10 ‘OM 10 -‘M 
that produces somatostatin. Somatostatin has been 
shown previously to prevent experimentally in- 
duced gastric ulcers, and in contrast to its usual 
inhibitory actions, has been found to enhance gas- 
tric mucus production [10,20]. Our currrent studies 
showing that SOS stimulates SLI release from the 
stomach via direct action on D-cells in the gastric 
mucosa support the hypothesis that sucralfate may 
mediate its effect through somatostatin. 
The action of SOS on isolated fundic D-cells re- 
sembles that of other neurohormonal stimuli of SLI 
release in that it is dose-dependent and potentiates 
the SLI response to agents that activate the CAMP 
messenger pathway, but influences only in additive 
fashion agents that act via the Ca2+/protein kinase 
C pathway. This would imply a direct receptor- 
mediated action of SOS linked to a calcium-depen- 
dent intracellular second messenger mechanism. 
Further studies are necessary to define the nature 
of this receptor and to confirm this intracellular 
mode of action. Nonetheless, the action of SOS is 
clearly not a nonspecific phenonomen since it is re- 
versible and D-cell selective. Moreover, it is not 
likely to be an artifact of the D-cell culture system, 
because it could be reproduced in the intact per- 
fused stomach. However, because our D-cell prepa- 
rations are not entirely pure, we cannot exclude the 
possibility that an intermediary target cell for SOS 
other than the D-cell sequentially stimulates SLI 
release. 
The relevance of our studies to the pharmacologic 
action of orally ingested sucralfate requires some 
scrutiny. The use of SOS for our studies seems rea- 
sonable in view of the observation that sucralfate, 
when placed in the acid milieu of the stomach, dis- 
sociates into its components aluminum ions and 
SOS [21]. The usual therapeutic doses of sucralfate 
are capable of producing local concentrations of 
SOS in the ranges described in our studies [2.5-20 
mg/mL]. Furthermore, D-cells in the gastric an- 
trum and possibly also in the fundus are known to 
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Figure 5. The effect of sucrose octasulfate (SOS] on somatostatin-like immunoreac- 
tivrty (SLI) release by the isolated perfused rat stomach. Data are represented as 
means * standard error (n = 5) of absolute SLI concentration (top) or percentage 
of control (bottom). *p <0.05, compared to basal (Student’s t-test for parred data.) 
IS0 = isoproterenol. 
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Figure 6. The effect of sucrose octasulfate (SOS) in combination with low-dose 
isoproterenol (ISO) (lo-’ M) on somatostatin-like immunoreactivity (SLI) secretion 
from the isolated perfused stomach. The data, provided in the same format as in 
Figure 5, represent means f standard error from five separate perfusions. SOS 
produced a response that was significantly greater than control on SLI secretion in 
response to low-dose isoproterenol. *p CO.05, compared to basal; tp 0.05, com- 
pared to isoproterenol alone. (Student’s f-test for paired data.) 
be of the “open” type; that is, they have apical 
membranes that extend to the lumen of the stom- 
ach [22]. Thus, D-cells are equipped to respond to 
stimuli present in the intragastric contents. This 
mechanism presumably accounts for gastric SLI 
release in response to intralumenal acidification 
[23]. Our perfused stomach studies were performed 
primarily to confii the observations made in iso- 
lated gastric D-cells. In these preparations SOS 
was administered arterially rather than lumenally 
and so may not have been physiologic. However, 
despite the notion that sucralfate is poorly ab- 
sorbed, there is evidence that a significant quantity 
of aluminum ions and possibly SOS also can enter 
the circulation when standard doses of sucralfate 
are administered by mouth [24]. The low doses used 
in the perfusion studies [10m7 M), therefore, may be 
a reasonable reflection of the amounts that circulate 
in plasma. 
Our studies provide novel insight into the cellular 
mechanisms by which sucralfate works as a thera- 
peutic or cytoprotective agent in the stomach. It is 
consistent with the hypothesis that sucralfate, act- 
ing through its constituent moiety SOS, stimulates 
release of SLI, which, in turn, promotes ulcer heal- 
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ing via a variety of mechanisms. Since virtually 
every other commonly used anti-ulcer therapy de- 
pends on inhibition or buffering of gastric acid, it is 
of note that SOS had no direct effect on acid secre- 
tion by gastric parietal cells. The remarkable evi- 
dence that SOS appears to act via specific receptor- 
mediated events to initiate SLI release from D-cells 
requires confutation and further exploration. 
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